Christopher Scott

Christopher T. Scott serves as a procurement professional responsible for managing research and development acquisitions within a federal agency focused on scientific innovation. He oversees the full lifecycle of contract actions, from requirements definition and market research to award and performance monitoring, with a primary emphasis on biotechnology and life sciences R&D. His work directly supports the agency’s mission to advance cutting-edge scientific capabilities through strategic sourcing of high-impact technical solutions. Scott routinely handles complex, performance-based contracts requiring specialized scientific expertise and compliance with federal acquisition regulations governing R&D services. His contractor relationships are primarily with firms specializing in biotechnological research, clinical development, and applied life sciences. While no single vendor dominates his portfolio, he engages a broad base of technical service providers, including academic research contractors, non-profit research institutes, and private-sector R&D firms with demonstrated capabilities in experimental design and data analysis. His procurement approach emphasizes competitive bidding and technical merit, fostering a dynamic marketplace of qualified vendors capable of delivering high-risk, high-reward scientific outcomes. Scott’s contracting patterns reflect a strong preference for open competition, with 95.7% of awards issued under full and open competition without set-asides. Only 4.3% of his awards are structured as total small business set-asides under FAR 19.5, indicating a selective but intentional approach to small business participation—typically reserved for firms with unique technical capabilities or proprietary methodologies not widely available among large contractors. His procurement focus is heavily concentrated in NAICS 541714 (Research and Development in Biotechnology), accounting for 80% of his activity, and NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences), which makes up the remaining 20%. He procures services such as preclinical testing, molecular diagnostics development, bioinformatics modeling, and translational research support, demonstrating deep domain expertise in life sciences innovation and regulatory-compliant R&D execution.